Monoclonal antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis are approved as both first- and second-line treatments for advanced NSCLC [9]. Here, CD274 is linked to non-small cell lung carcinoma.